Sanai Health Industry Group Co Ltd
01889
Company Profile
Business description
Sanai Health Industry Group Co Ltd is a pharmaceutical company. The company has three reportable segments namely Pharmaceutical products include development, manufacturing, marketing, and sales of pharmaceutical products and related software and provision of consultancy services. Finance leasing includes the provision of financial leasing services; Genetic testing and molecular diagnostic services segment. It generates maximum revenue from Pharmaceutical products segments. Geographically, it derives the majority of its revenue from the PRC.
Contact
57 Hung To Road
Unit 5, 7th Floor, Nanyang Plaza
Kwun Tong, Kowloon
Hong Kong
HKGSector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
147
Stocks News & Analysis
stocks
ASX healthcare giant remains well positioned despite share slump
We welcome the CEO change at CSL but relatively soft plasma performance will postpone recovery
stocks
Australian bank remains overvalued despite strong result
When strong fundamentals meet persistent valuation headwinds.
stocks
Chart of the Week: Soft earnings growth outlook for Australian banks
The latest take from our equity research analysts.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,281.80 | 97.30 | 1.06% |
| CAC 40 | 8,340.56 | 27.32 | 0.33% |
| DAX 40 | 24,852.69 | 3.46 | -0.01% |
| Dow JONES (US) | 49,736.01 | 385.39 | -0.77% |
| FTSE 100 | 10,417.06 | 55.05 | -0.53% |
| HKSE | 27,032.54 | 150.61 | -0.55% |
| NASDAQ | 22,671.63 | 394.83 | -1.71% |
| Nikkei 225 | 57,639.84 | 10.70 | -0.02% |
| NZX 50 Index | 13,531.48 | 85.11 | 0.63% |
| S&P 500 | 6,866.72 | 74.75 | -1.08% |
| S&P/ASX 200 | 9,043.50 | 127.50 | 1.43% |
| SSE Composite Index | 4,134.02 | 2.03 | 0.05% |